Purpose C-11 methionine (MET) PET is commonly used for diagnosing high-grade glioma (HGG). Recently, volumetric analysis has been widely applied to oncologic PET imaging. In this study, we investigated the prognostic value of metabolic tumor volume (MTV) on MET PET in HGG. Methods A total of 30 patients with anaplastic astrocytoma (n=12) and glioblastoma multiforme (n=18) who underwent MET PET before treatment (surgery followed by chemoradiotherapy) were retrospectively enrolled. Maximal tumorto-normal brain ratio (TNR max , maximum tumor activity divided by mean of normal tissue) and MTV (volume of tumor tissue that shows uptake>1.3-fold of mean uptake in normal tissue) were measured on MET PET. Adult patients were classified into two subgroups according to Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) classification. Prognostic values of TNR max , MTV and clinicopathologic factors were evaluated with regard to progression-free survival (PFS). Results Median PFS of all patients was 7.9 months (range 1.0-53.8 months). In univariate analysis, MTV (cutoff 35 cm 3 ) was a significant prognostic factor for PFS (P=0.01), whereas TNR max (cutoff 3.3) and RTOG RPA class were not (P=0.80 and 0.61, respectively). Treatment of surgical resection exhibited a borderline significance (P=0.06). In multivariate analysis, MTV was the only independent prognostic factor for PFS (P=0.03). Conclusion MTV on MET PET is a significant and independent prognostic factor for PFS in HGG patients, whereas TNR max is not. Thus, performing volumetric analysis of MET PET is recommended in HGG for better prognostication.
Introduction
High-grade glioma (HGG) is a rapidly progressing brain malignancy originating from glial cells. The incidence of HGG is less than 5 per 100,000 people a year [1] , which is approximately 1 % of all newly diagnosed cancers. Total resection can be a definite treatment for HGG [2] , and chemo-radiotherapy using temozolomide is commonly used as an adjuvant treatment [3] . However, HGG is very infiltrative, and complete resection is unavailable in most cases. The majority of HGG recurs within 1 year after initial treatment, and overall survival from HGG is very poor, despite the standard treatment [1] . For prognostication of HGG, age, pathologic type, Karnofsky performance status (KPS) score and genetic mutation patterns have been suggested as prognostic factors [4, 5] . Additionally, the Radiation Therapy Oncology Group Recursive Partitioning Analysis (RTOG RPA) criteria have been suggested [6] , in which pathologic type, KPS score and treatment options were included as prognostic factors.
C-11 methionine (MET) positron emission tomography (PET)/computed tomography (CT) is now widely used for detection, guidance of operation range, treatment efficacy monitoring and surveillance of recurrence in gliomas [7] [8] [9] . In a previous study, MET PET exhibited a sensitivity of 87 % and specificity of 89 % in detecting HGG, with a cutoff of 1.3 tumor-to-normal brain ratio (TNR) [10] . TNR values on MET PET have also exhibited correlations with pathologic types of glioma [11, 12] . Additionally, it has been reported in several studies that TNR on MET PET may be used for predicting prognosis of glioma [13, 14] . However, the prognostic value of TNR on MET PET still remains controversial.
In case of F-18 fluorodeoxyglucose (FDG) PET, volumetric analysis is widely used for evaluating the metabolic tumor burden in terms of treatment efficacy monitoring and prognostication [15, 16] . Volumetric analysis was also applied to MET PET in a study [17] where metabolic tumor volume (MTV) was measured in HGG by using TNR 1.3 as a cutoff for the isocontour tumor margin, and it was reported that MTV exhibited a significant correlation with the volume measured on contrast-enhanced magnetic resonance imaging (MRI) [17] .
In the present study, we measured MTV on MET PET in HGG patients in addition to TNR, a metabolic index, and investigated their prognostic values for progression-free survival (PFS) in comparison with several clinicopathologic parameters.
Materials and Methods

Patients
From January 2008 to December 2013, HGG patients who underwent MET PET as an in initial evaluation in our institution were retrospectively enrolled. In case MET PET was performed during or after treatment, the patient was excluded from the study. All patients underwent stereotactic biopsy and/or surgical resection, and diagnosis was confirmed by histopathological review of tumor tissues. After surgical treatment, patients received standard chemo-radiotherapy using temozolomide and irradiation of 45-61 Gy. As a clinical prognostic index, adult patients were classified by the RTOG RPA criteria [6] : low RTOG RPA class (class 1-3), and high RTOG RPA class groups (class 4-6).
The study design was approved by the Institutional Review Board of our institution, and written informed consents were waived.
Image Acquisition and Analysis
MET PET scans were performed at 1-32 days (median 7 days) before stereotactic biopsy or surgical resection. After 6-h fasting, MET (5.55 MBq/kg) was injected intravenously, and the PET/CT scan was started 10 min after injection. Using hybrid PET/CT scanners (Biograph mCT40 and Biograph mCT64; Siemens Medical Solution, Erlangen, Germany), a low-dose CT scan (120 kVp, 50 mAs) was acquired for attenuation correction and lesion localization. Afterwards, brain PET images were acquired for 20 min for one bed position. CT images were reconstructed into 5-mm slice thickness, and PET images were reconstructed on 200×200 matrices using an iterative algorithm (iteration 2, subset 21).
MET PET/CT images were reviewed by two experienced nuclear medicine physicians and semiquantitatively analyzed using a vendor-supplied analyzing software package (Syngo.via, Siemens Medical Solutions, Erlangen, Germany). A spherical volume of interest (VOI) with 10-mm radius was manually drawn to include the maximal activity in the tumor. The same VOI was drawn in the unaffected contralateral cerebral parenchyma to measure activity of the normal brain (Fig. 1) . TNR was calculated as the ratio between the uptake activities of tumor tissue and the normal brain, and maximum TNR (TNR max ) was deemed to be a marker for metabolic activity. For volumetric analysis, an isocontour VOI was automatically drawn around a tumor by using TNR 1.3 as a threshold, based on a previous report [17] . The volume of this VOI was defined as MTV and deemed to be a marker for metabolic tumor burden.
Follow-Up of Patients
Clinicopathologic data of all patients were obtained from review of medical records. Information on age, gender, KPS score, histopathological findings including MGMT methylation, tumor size (the longest diameter) measured on MRI and selected treatment options was obtained. During follow-up, brain MRI was performed periodically (every 2-3 months) and when abnormal neurologic symptoms or signs were presented. When tumor size was increased or any new lesion was detected on MRI, it was defined as tumor progression. PFS was defined as the time between the dates of initial MET PET and confirmation of tumor progression.
Statistical Analysis
All data are expressed as mean±SD. Comparison of values between two subgroups was performed using Student's t-test. Kaplan-Meier survival analysis was used for survival curve plotting. Additionally, log-rank test and Cox proportional hazard regression analysis were used to evaluate the efficacy of prognostic factors, in univariate and multivariate analyses, respectively. For survival analysis, optimal cutoff values for TNR max and MTV were determined from iterative pilot analyses. In brief, the median value was used as the first cutoff value for a survival analysis. Afterward, the next values to the tested cutoff values were used as the cutoff values for survival analysis, and the P-values were compared between the cutoff values. This process was repeated, and the cutoff values for the lowest P-values were selected as the optimal cutoff values.
Statistical analysis was performed using a commercial statistics software package (SPSS Statistics 21.0 for Windows, IBM Corp., NY, USA). P-values less than 0.05 were regarded as significant.
Results
Patients
A total of 30 patients (21 males and 9 females) were included in the final analysis. Among them, 12 had anaplastic astrocytoma and 18 glioblastoma multiforme. The patients were followed up for 1.0-53.8 months; tumor progression was observed in 26 patients at 7.6 ± 5.7 months (range; 1.0-24.0 months) during follow-up. In four patients, there was no tumor progression, and median PFS in overall patients was 7.9 months. Patient characteristics are summarized in Table 1 . Thirteen patients received only chemo-radiotherapy with temozolomide after stereotactic biopsy, and 17 patients underwent near-total or total resection of the tumor. Among them, 14 patients received postoperative adjuvant chemoradiotherapy, and 3 patients received postoperative radiotherapy only because of poor general condition. 
Image Findings
In all patients, TNR max and MTV were successfully measured. In overall patients, TNR max was 3.6±1.4 (range 1.8-6.9), and MTV was 39.1±51.4 cm 3 (range 0.02-265.7 cm 3 ). When patients were classified by RTOG RPA criteria, there was a significant difference in TNR max between low and high RTOG RPA class groups (P=0.02), whereas no significant difference existed in MTV (P=0.71, Table 2 ).
Survival Analysis
In the iterative pilot analyses, 3.3 and 35 cm 3 were selected as the optimal cutoff values for TNR max and MTV in prognosis prediction. In univariate analyses of overall patients, MTV was a significant prognostic factor for PFS (P = 0.01, Fig. 2a ), whereas TNR max was not significant (P =0.80, Fig. 2b ). RTOG RPA class was also not a significant prognostic factor (P=0.61, Fig. 2c ). In contrast, history of resection exhibited a borderline significance, although it was negative (P=0.06). None of the other tested clinicopathologic parameters of age, gender, histopathology, tumor size, KPS score, and MGMT methylation was significant in predicting PFS (Table 3) .
Among the tested parameters, multivariate analysis was performed for five parameters: four most significant parameters (MTV, treatment, histopathology and KPS score) and one clinical prognostic index (RTOG RPA class). In the multivariate analysis, MTV was selected as the only independent prognostic factor for PFS, and the hazard ratio of high MTV was 2.55 (range 1.09-5.98, Table 3 ). Representative cases are shown in Fig. 3 .
Discussion
The aim of the present study was to investigate prognostic value of metabolic and volumetric indices on MET PET in HGG compared to other clinicopathologic parameters. As a result, MTV was demonstrated to be the only significant and independent prognostic factor for PFS in HGG.
MET PET has been reported to be effective in HGG in terms of lesion detection, margin delineation and differentiation from treatment-induced necrosis. In most such studies, TNR was utilized as a quantitative index for metabolic activity [10, 19, 20] . Several studies have reported that there is a correlation between aggressiveness of glioma and TNR [21, 22] , and TNR also exhibited correlations with prognosis in several studies [13, 14] . However, the prognostic value of TNR on MET PET still remains controversial.
Volumetric analysis of FDG PET has been performed in treatment efficacy monitoring and prognostication of diverse cancers [23, 24] . Because MTV reflects the overall tumor burden, it has been reported to have a higher prognostic value than the maximal standardized uptake value (SUV). Based on these results, volumetric analysis was also applied to MET PET in glioma patients in several studies [17, 18, 25] , some of which reported that MTV has a higher prognostic value for overall survival than TNR [18, 25] . In TNR max maximum tumor-to-normal ratio, MTV metabolic MET uptake volume, PFS progression-free survival Fig. 2 Survival curves according to the tested prognostic factors. MTV (a) was a significant prognostic factor for PFS, whereas TNR max (b) and RTOG RPA classification (c) were not the present study, we analyzed the prognostic value of MTV regarding PFS in HGG patients who were treated according to the standard treatment protocol and demonstrated a similar prognostic value of MTV. In this study, MTV on MET PET was identified as the only significant and independent prognostic factor for PFS in HGG patients. However, other clinicopathologic factors including age, sex, pathologic type, RTOG RPA classification and KPS score were not significant prognostic factors, although RTOG RPA classification has been reported to be a significant prognostic factor in several previous studies [6, 18] . It is speculated that the result may be the small case number of our study, which was not enough for high statistical power. TNR max was also not a significant factor for prognosis, whereas treatment option exhibited a borderline significance. However, it should be noted that MTV was a significant factor in both univariate and multivariate analyses, despite probable low statistical power. Further studies with larger case numbers are warranted regarding the prognostic vale of volumetric analysis on MET PET.
When TNR max , MTV and PFS were compared between the high and low RTOG RPA class groups, there was a significant difference only in TNR max between the two groups. Because pathologic type, KPS score and age are included in the RTOG RPA criteria, this appears to be in accordance with previous reports that TNR reflects the pathologic type of glioma [11, 12] . MTV and RTOG RPA class did not exhibit a significant correlation with each other probably because the RTOG RPA criteria do not include tumor size or burden; moreover, MTV is considerably different from anatomical tumor burden.
In the present study, we performed volumetric analysis using an isocontour VOI as performed in previous volumetric analysis studies on FDG PET. We adopted TNR 1.3 as a threshold for isocontour, whereas a certain value of SUV or a certain percentage of maximal SUV is used on FDG PET. In case of MET PET, SUV is not a reliable index for amino acid metabolism of glioma because of a large interindividual variation of neutral amino acids in plasma [20, 26] . These amino acids are not distinguished from MET by the amino acid transporter, which results in a variation in overall amino acid uptake. Thus, TNR has been adopted in many studies on MET PET, and TNR 1.3 was reported to be effective in differentiating HGG with high diagnostic performance [10] . TNR 1.3 was also adopted in previous volumetric analysis studies on MET PET [17, 18] ; thus, we adopt this cutoff value in the present study. However, further studies are required to determine an optimal method for volumetric analysis on MET PET.
This study has several limitations. First of all, the case number is relatively small, although the prognostic value of MTV was statistically significant. Further studies with larger case numbers are required to confirm the prognostic values of metabolic and volumetric indices on MET PET. Second, our study included relatively many pediatric patients, which may have been a bias factor because several studies have reported a slightly better prognosis of HGG in younger patients [4, 27, 28] . The difference in prognosis was reported to depend on the clinicopathologic factors, genetic mutation profiles and location of tumors, most of which were statistically controlled in our study. However, it should be noted that the MTV value would have a different implication between adult and pediatric patients 
Conclusion
In conclusion, MTV on MET PET is a significant and independent prognostic factor for PFS in HGG patients, whereas TNR max is not. Thus, volumetric analysis of MET PET needs to be performed in HGG for better prognostication.
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